| 05/16 | INSIDER SELL : Seagen | MT |
| 05/16 | Seagen's President, CEO Clay Siegall Resigns Amid Investigation | MT |
| 05/13 | SECTOR UPDATE : Health Care Stocks Gain Premarket Friday | MT |
| 05/13 | Swiss Medical Regulator Approves Moderna's Covid-19 Vaccine for 6-11-Year-Olds | MT |
| 05/13 | Swissmedic OKs Moderna's COVID-19 Jab For Children Aged Six To 11 Years | MT |
| 05/13 | N.Korea gets offers of aid to fight COVID as it lacks vaccines | RE |
| 05/13 | Switzerland authorizes Moderna's COVID vaccine for 6-11 year olds | RE |
| 05/11 | Moderna completes FDA submission for use of COVID shot in adolescents, kids | RE |
| 05/11 | Moderna, Inc. Fires Jorge Gomez as CFO | CI |
| 05/11 | Pfizer's $11.6 billion Biohaven buy could spark more biotech deals | RE |
| 05/11 | Moderna Ousts New Finance Chief Amid Probe at Dentsply | DJ |
| 05/11 | Moderna Says Recently Named CFO Jorge Gomez Departs; David Meline Continues as CFO | MT |
| 05/11 | Moderna CFO, Jorge Gomez, Resigns Effective Immediately | MT |
| 05/11 | Moderna CFO exits a day after taking charge as former employer launches probe | RE |
| 05/11 | Moderna's new CFO Jorge Gomez steps down | RE |
| 05/10 | What you need to know about the coronavirus right now | RE |
| 05/10 | Novavax shares slide 20% on COVID vaccine demand uncertainty | RE |
| 05/09 | Lonza, ALSA Ventures Partner To Support Development Of Small Molecule Drug Candidates | MT |
| 05/09 | Novavax 2022 COVID vaccine deliveries off to slow start, shares drop | RE |
| 05/09 | Novavax posts drop in COVID research funding, slow start to 2022 vaccine delivery | RE |
| 05/09 | SECTOR UPDATE : Health Care Stocks Declining Ahead of Monday Close | MT |
| 05/09 | SECTOR UPDATE : Health Care | MT |
| 05/09 | Seagen's Shares Drop After CEO Clay Siegall Takes Leave of Absence; Roger Dansey Named .. | MT |
| 05/09 | Top Midday Decliners | MT |
| 05/09 | Equities Drop Midday as Economic Growth, Inflation Concerns Mount | MT |
| 05/09 | Seagen CEO Clay Siegall Takes Leave of Absence; Roger Dansey Named Interim CEO | MT |
| 05/09 | COVID vaccine makers shift focus to boosters | RE |
| 05/09 | Seagen Inc. Announces CEO Changes | CI |
| 05/09 | Seagen President, CEO and Chairman Clay Siegall Takes Leave of Absence | CI |
| 05/06 | Obesity may weaken vaccine protection; unvaccinated Omicron patients face risk from var.. | RE |
| 05/06 | EuroAPI gains on market debut after spin-off from Sanofi | RE |
| 05/05 | U.S. limits use of J&J's COVID vaccine on blood clot risks | RE |
| 05/05 | TikoMed AB and IQVIA Announce Strategic Collaboration for the Development of TikoMed's .. | CI |
| 05/04 | INSIDER SELL : Moderna | MT |
| 05/04 | Moderna Beats First-Quarter Views on Vaccine Sales Surge, Sees Need For Booster Doses i.. | MT |
| 05/04 | TRANSCRIPT : IQVIA Holdings Inc. - Special Call | CI |
| 05/04 | SECTOR UPDATE : Health Care Stocks Climb Pre-Bell Wednesday | MT |
| 05/04 | TRANSCRIPT : Moderna, Inc., Q1 2022 Earnings Call, May 04, 2022 | CI |
| 05/04 | Moderna's Q1 Earnings, Revenue Rise -- Shares Gain Pre-Bell | MT |
| 05/04 | Moderna sees higher COVID vaccine sales later this year | RE |
| 05/04 | Moderna, Inc. Reports Earnings Results for the First Quarter Ended March 31, 2022 | CI |
| 05/04 | Moderna keeps full-year COVID vaccine sales view unchanged | RE |
| 05/04 | Earnings Flash (MRNA) MODERNA Posts Q1 Revenue $6.07B, vs. Street Est of $4.426B | MT |
| 05/03 | Declaration of Voting Results by Moderna, Inc | CI |
| 05/02 | Moderna says its vaccine for ages under 6 will be ready for U.S. review in June | RE |
| 05/02 | Poland has no 'rationale to invoke force majeure in Pfizer vaccine deal -EU official | RE |
| 05/02 | Moderna's COVID-19 Vaccine For Children Under Six To Be Ready For US FDA Review In June | MT |
| 04/29 | RBC Capital Adjusts Seagen's Price Target to $136 From $132, Maintains Sector Perform R.. | MT |
| 04/29 | Moderna Seeks European Nod for COVID-19 Vaccine for Kids Under Six | MT |
| 04/29 | IQVIA Holdings Shares Rise Midday Following Piper Upgrade, Target Increase | MT |
English (UK)
English (Canada)
Deutsch (Deutschland)
Deutsch (Schweiz)
Español
Français (France)
Italiano
Nederlands (Nederland)
Nederlands (België)
